厄贝沙坦氢氯噻嗪与福辛普利治疗原发性高血压的疗效观察

Efficacy of Irbesartan Hydrochlorothiazide and Fosinopril in the Treatment of Essential Hypertension

目的探讨厄贝沙坦氢氯噻嗪治疗原发性高血压的效果。方法选取2017年1月～12月我院收治的120例原发性高血压患者作为研究对象,按照随机数字表法分为对照组和实验组,每组60例。对照组给予福辛普利治疗,实验组给予厄贝沙坦氢氯噻嗪治疗,观察两组的治疗总有效率、血压改善情况及不良反应发生率。结果实验组患者的临床总有效率为96.67%,优于对照组的75.00%;实验组患者血压水平改善情况更为理想,实验组不良反应发生率为5.00%,低于对照组的15.00%,差异具有统计学的意义(P<0.05)。结论厄贝沙坦氢氯噻嗪治疗原发性高血压疾病疗效确切且较安全,可以作为治疗原发性高血压的首选药物。

Objective To investigate the effect of irbesartan hydrochlorothiazide in the treatment of essential hypertension.Methods 120 patients with essential hypertension admitted in our hospital from January to December 2017 were selected as study subjects.According to the random digital table method,they were divided into the control group and the experimental group two groups,60 cases in each group.The control group was treated with fosinopril and the experimental group with irbesartan hydrochlorothiazide.The total effective rate,the improvement of blood pressure and the incidence of adverse reactions were observed.Results The total effective rate of the patients in the experimental group was 96.67%,which was better than that in the control group 75.00%;The incidence of adverse reactions in the experimental group was 5.00%,which was lower than that in the control group 15.00%,the difference was statistically significant(P<0.05).Conclusion Irbesartan hydrochlorothiazide is effective and safe in the treatment of essential hypertension.It can be used as the first choice for the treatment of essential hypertension.